Zobrazeno 1 - 8
of 8
pro vyhledávání: '"James Witek"'
Autor:
Robert Herring, Aasim Sheikh, Eric M. Yoshida, Reem Ghalib, Guy De La Rosa, Hillel Tobias, Eliot Godofsky, Oliver Lenz, Monika Peeters, Gary Matusow, Rekha Sinha, Jane Scott, Bart Fevery, James Witek, Eric Lawitz, Franco Felizarta, Gary Poleynard, R. Kalmeijer, Marcelo Kugelmas, Edwin DeJesus
Publikováno v:
Hepatology (Baltimore, Md.)
UNLABELLED Hepatitis C virus (HCV)-infected patients with cirrhosis are historically a difficult-to-treat population and are at risk of hepatic decompensation. In the phase 2 COSMOS study that evaluated simeprevir (HCV NS3/4A protease inhibitor) + so
Autor:
Christoph Sarrazin, Simone Susser, Mathieu Flinders, Henk W. Reesink, Glenn Lawyer, Stefan Zeuzem, Anne Ghys, James Witek, Veerle Van Eygen, Sandra De Meyer
Publikováno v:
Antimicrobial agents and chemotherapy, 59(5), 2746-2755. American Society for Microbiology
In treating hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections, the rapid reselection of resistance-associated variants (RAVs) is well known in patients with repeated exposure to the same class of antiviral agents. For chronic
Autor:
Annemie Buelens, Bart Fevery, James Witek, Erkki Lathouwers, Yves Wyckmans, Anne Ghys, Oliver Lenz, Alessandra Baldini, Christoph Sarrazin, Monika Peeters, M. Schlag, Bjorn Daems, Thierry Verbinnen, Sandra De Meyer
Publikováno v:
Antiviral Research. 116:10-16
Hepatitis C virus (HCV) NS3 polymorphism Q80K is mainly found in patients with HCV genotype (G) 1a, and has been associated with a reduced treatment response to simeprevir with pegylated interferon (P) and ribavirin (R). Prevalence of Q80K among G1 p
Autor:
Kim Thys, Veerle Van Eygen, Annemie Buelens, James Witek, Oliver Lenz, Jeroen Aerssens, Sandra De Meyer, Bart Fevery, Elizabeth Van Rossem, Gaston Picchio, Thierry Verbinnen
Publikováno v:
Open Forum Infectious Diseases
Deep sequencing analyses in HCV genotype 1-infected patients treated with simeprevir/peginterferon/ribavirin showed that pre-existing minority HCV variants did not impact treatment outcome and emerging resistant variants in patients failing treatment
Autor:
Bart Fevery, Katrien Janssen, Thierry Verbinnen, W. Jessner, S. De Meyer, James Witek, Oliver Lenz, Monika Peeters
Publikováno v:
Journal of viral hepatitis. 24(1)
Summary Simeprevir is a hepatitis C virus NS3/4A protease inhibitor. Hepatitis C virus baseline NS3/4A polymorphisms and emerging mutations were characterized in treatment-naїve and treatment-experienced genotype 4-infected patients treated with sim
Autor:
Donghan Luo, I. Dierynck, Gaston Picchio, James Witek, Bjorn Daems, Anne Ghys, Maria Buti, S. De Meyer, Katrien Janssen
Publikováno v:
Journal of viral hepatitis. 21(12)
The OPTIMIZE study demonstrated noninferior efficacy between telaprevir (TVR) twice daily (bid) vs every 8-h (q8h) administration. This analysis compared the selective pressure of both dosing regimens by characterisation of the hepatitis C virus (HCV
Publikováno v:
AIDS research and human retroviruses. 28(6)
The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We pres
Autor:
Michael Sension, Michael S. Gottlieb, Michael Wohlfeiler, Annemie Hoogstoel, Jonathan S Appelbaum, Steven Nijs, William J. Towner, Paul Bellman, Rodica Van Solingen-Ristea, Joseph Gathe, Robert Ryan, Jacob Lalezari, James Witek
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 53(5)
Etravirine, a nonnucleoside reverse transcriptase inhibitor, was provided through an international early access program (EAP) prior to regulatory approval.The Phase III, nonrandomized, open-label EAP investigated etravirine 200 mg twice daily plus a